Healthcare Practice Loans – Call 904-551-6090: A Cheaper Alternative to Hearing Aids? + MORE 07/06/2017

HealthCare Professional financing for your medical practice!  Learn how to get working capital funding with medical practice financing. More Info Here!

Call: 904-551-6090

Over the years we have been able to finance a lot of start up medical practice units with excellent services. The great repayments rates that are stated by the company will give you the chance to order your finances well. All the low repayment rates are aimed at financing your financial program by virtue that it was specifically designed to help fresh medical doctors who are in need of financial assistance to start up their medical practice. With confidence, you should make our company your financial source as we are dedicated to make your dreams a reality.

Read The Interesting Snippets Below For Exciting Health-Care News!

Target is still in place despite being missed in manifestoRelated items from OnMedicaPolitical pledges on GP numbers ‘will take decades’Practices struggling to recruit can access up to £12KGP leader urges caution over ‘super-hub’ general practice Indemnity costs may lead GPs to quit general practiceGeneral practice still on brink of collapse, warn GP leaders

Continue Reading On »

Devices performed almost as well and are much cheaper, but they aren’t regulated, researchers note

Continue Reading On »

Small study found an association but didn’t prove link

Continue Reading On »

(Reuters Health) – After weight-loss surgery, people who get cosmetic procedures to remove excess tissue may have a better quality of life than those who don’t get this additional work done, a recent study suggests.

Continue Reading On »

A novel class of personalized cancer vaccines, tailored to the tumors of individual patients, kept disease in check in two early-stage clinical trials, pointing to a new way to help the immune system fight back.

Continue Reading On »

Action needed on misleading advertising of unproven therapiesRelated items from OnMedicaCracking down on health tourismParalysed man walks after stem cell breakthrough NHS ‘confident’ of funding stem cell treatmentStem cell transplant shows promise for MS outcomesNHS cancer patients still denied treatments available in other countries

Continue Reading On »

Updated Posts

Nation-Wide Doctor Office Building Financing - Call: 904-551-6090 + More: U.S. employers say CVS-Aetna deal would affect health-benefits decisions: survey + MORE 12/18/2017

NEW YORK (Reuters) - CVS Corp’s proposed purchase of Aetna Inc will affect decision-making by a majority of large and mid-size U.S. corporations on employee health benefits, a survey by benefits consultant Aon Plc found. .... More »

Nation-Wide Doctor Office Building Financing - Call: 904-551-6090 + More: Sanofi expects $120 million hit as dengue vaccine hits major snag + MORE 11/30/2017

PARIS (Reuters) - Use of Sanofi's dengue vaccine, the world's first approved shot against the mosquito-borne virus, is to be strictly limited due to evidence it can worsen the disease in people who have not previously been exposed to the infection. The French drugmaker said in a statement on Wedn.... More »

Doctor Practice Financing - Call: 904-551-6090 + More: FDA OK's New Drug for Antibiotic-Resistant UTIs + MORE 09/02/2017

The FDA approved a new drug called Vabomere, meant for serious, antibiotic-resistant urinary tract infections..... More »

Nation-Wide Doctor Office Building Financing - Call: 904-551-6090 + More: FDA declines to approve Intellipharma's opioid painkiller + MORE 09/25/2017

(Reuters) - Intellipharmaceutics International Inc said on Monday the U.S. Food and Drug Administration (FDA) declined to approve its long-acting opioid painkiller in its current form, backing its independent advisory panel that had raised concerns over the drug's abuse-deterrence capabilities. .... More »

Healthcare Practice Loans - Call 904-551-6090: Vernalis hit by fresh U.S. setback for cough and cold drug + MORE 08/07/2017

LONDON (Reuters) - Shares in Vernalis fell more than 15 percent on Monday as the British biotech company backed by fund manager Neil Woodford and his previous employer Invesco announced a fresh setback for a key new drug in the United States. .... More »